BL-B01D1 is a bispecific ADC targeting EGFR and HER3, which induces cell cycle arrest in the S phase and subsequent apoptosis, leading to kill EGFR+ and/or HER3+ tumor cells. Here, ERBB3 is linked to neoplasm.